...
首页> 外文期刊>Vaccine >Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains
【24h】

Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains

机译:重组HVT-H5疫苗针对两种抗原分歧的埃及进化枝2.2.1 HPAI H5N1菌株的攻击提供的抗原漂移和保护功效的进一步证据

获取原文
获取原文并翻译 | 示例

摘要

In this study, we have compared the protection afforded by a recombinant turkey herpesvirus vaccine expressing the H5 gene from a clade 2.2 H5N1 strain (rHVT-H5) and a Mexican-origin H5N2 inactivated vaccine, alone or in combination, against two antigenically divergent H5N1 Egyptian strains isolated in 2007 and 2008. Our results confirm the existence of a major antigenic drift among the Egyptian H5N1 strains such that, although protection against the "classical" 2007 HPAI H5N1 Egyptian strain could be obtained with both types of vaccines, only vaccination with the rHVT-H5 vaccine protected against challenge with the "variant" 2008 HPAI H5N1 Egyptian strain
机译:在这项研究中,我们比较了表达2.2进化枝H5N1株(rHVT-H5)的H5基因的重组火鸡疱疹病毒疫苗和单独或组合使用的墨西哥产H5N2灭活疫苗对两种抗原性不同的H5N1的保护作用。埃及毒株于2007年和2008年分离。我们的结果证实了埃及H5N1毒株中存在主要的抗原漂移,因此,尽管可以通过两种类型的疫苗获得针对“经典” 2007 HPAI H5N1埃及毒株的保护,但仅需接种rHVT-H5疫苗可抵抗“变异” 2008 HPAI H5N1埃及毒株的攻击

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号